Depriving cells of glutamine sensitizes prostate cancer cells to radiotherapy and kelch like ECH associated protein 1 (KEAP1)‐mutant lung adenocarcinoma.[8] Furthermore, targeting glutamine metabolism at the transporter level[9] and enzymes involved in glutamine synthesis and catabolism[10] offers a promising approach for refining cancer medicine. The gene discussed is KEAP1; the disease is prostate carcinoma.